Evidence map›Paper›PMID 41012587›Full record

ReviewViruses2025

Epitranscriptomic Regulation of Hepatitis B Virus by RNA 5-Methylcytosine: Functions, Mechanisms, and Therapeutic Potential.

Xuliu Zhou, Yanling Huang, Xueyan Zhang, Wuxiang Guan, Fang Zhang, Haojie Hao

Abstract readReview
In one paragraph

Review in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xuliu ZhouSchool of Pharmacy, Hubei University of Chinese Medicine, Wuhan 430065, China.
Yanling HuangCenter for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.
Xueyan ZhangCenter for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.
Wuxiang GuanCenter for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.
Fang ZhangHubei JiangXia Laboratory, Wuhan 430200, China.
Haojie HaoCenter for Emerging Infectious Diseases, Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan 430071, China.

Funding

Hubei Jiangxia Laboratory Biosafety Key R&D Project JXBS013Hubei Jiangxia Laboratory Research Startup Funding Project E3ZFJX0101National Key Research and Development Program 2024YFC2309400Natural Science Foundation of Hubei Province 2024AFB1065Strategic Priority Research Program of the Chinese Academy of Sciences XDB0490000
6 · The paper itself

Abstract

Hepatitis B virus (HBV) remains a major global health challenge, with over 296 million people chronically infected worldwide. Despite the availability of antiviral therapies, a functional cure is rarely achieved, highlighting the need for novel therapeutic strategies. RNA 5-methylcytosine (m

Indexed as

5-MethylcytosineEpigenesis, GeneticGene Expression Regulation, ViralHepatitis B virusRNA, ViralTranscriptomeAntiviral AgentsHepatitis BHumansRNA Stability5-MethylcytosineAntiviral AgentsRNA, Viral5-methylcytosine (m5C)hepatitis B virus (HBV)hepatocellular carcinoma (HCC)NSUN2RNA modificationviral replication

Identifiers

PMID41012587
PMCPMC12474464

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.